Background: Adverse drug reactions (ADR) are severe problems in global public
Introduction
Adverse drug reactions (ADR), injurious consequences resulting from medications in proper therapeutic use, are an important population health problem worldwide. [1] [2] [3] [4] The term ADR is used here to refer to the causal connections between the proper use of medications and adverse events, excluding those due to medication errors. ADR are associated with potentially preventable morbidities and mortality, placing a substantial burden on the healthcare systems in Australia 5, 6 as well as internationally. [2] [3] [4] 7, 8 Previous studies showed different patterns of ADR using routinely collected hospitalisation data. [8] [9] [10] [11] [12] [13] Studies in the United States, 11 United Kingdom 9,10 and Portugal 13 indicated that the total number of ADR-related admissions increased over time, while other studies have shown a decreasing incidence of ADR. 8 Using Western Australia hospital inpatient data from 1981 to 2002, Burgess et al. 12 reported an increase in the incidence rate of ADR from 2.5 to 12.9 per 1000 persons among patients aged 60 years and over. Evidence suggests that up to 30% of hospital admissions among adults aged 65 years and over were attributed to inappropriate prescribing. 5 There is a lack of data on the recent trends of ADR-related hospitalisations in Australia. Moreover, it is not clear how ADR-related hospitalisations change over time and vary by patient characteristics and medications. Knowledge of such patterns is needed to provide future directions for improvement, prioritise prevention strategies and potentially reduce the healthcare burden in targeted populations.
Using a population-based, state-wide inpatient data collection, we aimed to examine trends in ADR-related hospitalisations in New South Wales (NSW), the most populous state in Australia. Findings may have implications for ADR countermeasures to reduce the associated healthcare burden.
Methods

Data sources
We used the NSW Admitted Patient Data Collection (APDC) during the period of July 2001 to June 2014. Maintained by the NSW Health Department, the APDC is a complete census of hospital separations in NSW.
14 It covers all public, private and repatriation hospitals and private day procedure centres in NSW. The APDC comprises information and activities of admitted patients, including demographic information and clinical information. Medical reasons for hospital admission were coded at the time of separation using the Australian modification of the 10th version of International Statistical Classification of Diseases and Related Health Problems (ICD-10 AM), a coding systems widely used in identifying the global trends of diseases and other health-related conditions.
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Based on the data use agreement with the NSW Health Department, for each de-identified separation record, we extracted the patient's age, gender, urgency of admission, dates of admission, dates of separations, up to 53 medical diagnoses and separation mode. The Australian National University Science & Medical Delegated Ethics Review Committee approved this study (#2016/030).
Definitions
We selected ADR-related hospitalisations using ICD-10 AM codes (Y40-Y59) from Chapter XX 'External causes of morbidity and mortality' because these episodes of care were caused by the 'drugs, medicaments and biological substances in proper therapeutic use'. We further selected cases having a validated medicine-induced diagnosis, 16 with the intention to capture fully all ADRrelated hospitalisations. There were multiple updates to the ICD-10 AM during the study periods, which did not affect these codes.
As the APDC comprised de-identified episodes of care, we only considered hospitalised cases for acute care to reduce the impact of multiple counting. Subjects with unknown age and gender were excluded. We categorised age into five groups, that is, children under 18 years old, young adults between 18 and 44 years, older adults between 45 and 64 years, old-olds between 65 and 84 years or the oldest at 85+ years; gender as male or female and severity of comorbidities using Charlson Comorbidity Index 17 as minor (Charlson score equal to 0), moderate (Charlson score equal to 1 or 2) or severe (Charlson score ≥ 3). We also used the separation mode to identify cases that died at hospital, had been discharged home or had been transferred.
To investigate if ADR-related hospitalisation trends would vary across different medications as potential ADR causes, we categorised medications into 20 therapeutic groups (column 1, Table 2 ) according to the ICD-10 categories of external causes (Y40-Y59). 18 We further categorised the primary diagnosis as the clinical condition that warrants the hospitalisation into selected condition groups according to ICD-10 AM diagnosis codes (i.e. A-B: Infections; C: Cancers; D5-D9: Blood immune systems; E: Endocrine system; F: Mental and behavioural disorders; G: Nervous system; H: Eyes and ears; I: Circulatory system; J: Respiratory system; K: Digestive system; L: Skin conditions; M: Musculoskeletal disorders; N: Genitourinary system; R: Symptoms and signs or S-T: Injury and poisoning), which might be secondary to the ADR, to investigate if trends would vary across different diagnostic groups as the potential ADR-related clinical consequences. Whilst external cause codes indicate ADR occurrence in relation to different medications, these clinical diagnosis codes indicate ADR symptoms and signs, reflecting various unintended consequences during normal pharmaceutical therapies that require acute hospital care.
Statistical analysis
We used the annual percentage change (APC) estimator to evaluate trends of age-adjusted rates over time for ADR-related hospitalisations, which is robust regardless of either linear or nonlinear change assumption. 18 We calculated the number of all ADR-related episodes of care as the numerator. Individual case counts, for example, by disease groups or medication groups were based on the subset of total cases that had the relevant codes as described in the definition. Multiple definitions within one case were counted separately; for example, a case may be counted if having a diagnosis of cancer or if having an imaging service. As APDC is financial year-based data collection (1 July current year to 30 June following year), annual incidence rate of ADR-related episodes of care was defined as the number of annual incident cases divided by the end of calendar year population estimated by Australian Bureau of Statistics census in NSW during the period [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] [2013] [2014] . Considering that population age structure may change over time, we directly calculated age standardised rates using the Australian Bureau of Statistics 2001 standard population. 19 Jointpoint Software was used to calculate age-adjusted rate, APC and corresponding 95% CI. 20 The age-adjusted rate of ADR-related hospitalisations almost doubled from 220.2 to 432.3 per 100 000 NSW residents, with an annual percentage increase of 5.8% (95% CI: 5.0-6.6%). ADR-related hospitalisations increased to a greater extent in males (APC: 6.0%, 95% CI: 5.2-6.9%) than females (5.6%, 4.8-6.4%). Adults aged between 65 and 84 years accounted for nearly half of ADR hospitalisations (45.6%), with an estimated annual increase of 5.1% (95% CI: 4.3-5.9%) ( Table 1) .
Results
Patient characteristics
Among all ADR-related hospitalisations, there were 167 496 (53.13%) cases with comorbidities diagnosed as being minor, with the greatest increase of 6.9% per annum (5.1-8.7%) as opposed to an increase of 4.1% (2.4-5.9%) in those with moderate comorbidities and 5.1% (2.5-7.8%) with severe comorbidities (Table 1) .
Approximately 77.2% (n = 243 300) of ADR-related hospitalisations were discharged home, representing an increase of 5.7% (4.9-6.5%) per annum. A total of 10 363 patients, accounting for 3.3% of all ADR-related hospitalisations, died during their episodes of care, with an increase of 2.4% (95% CI: 1.6-3.3%) per annum (Table 1) . Figure 1 showed leading medications (% of all agents) contributing to ADR-related hospitalisation during the study period. It was also shown that anticoagulants were consistently the most common medications contributing to 13.5% of all ADR-related hospitalisation during the study period, followed by opioids and related analgesics (9.6%) (Fig. 1) . Figure 2 demonstrates examples of trends for ADR hospitalisation in relation to anticoagulants, opioids and related analgesics and antineoplastic antibiotics during the study period. The leading therapeutic groups that caused hospitalisation did not vary extensively over time (Table 2) , with the analgesics group accounting for 15.2% (n = 46 500) of total hospitalisations, followed by agents primarily affecting blood constituents (14.9%, n = 45 596), agents primarily affecting the cardiovascular system (14.3%, n = 43 799) and systemic antibiotics (10.9%, n = 33 266). These leading causes of ADRrelated hospitalisations all demonstrated an increasing trend over time, with the greatest increase of 11.2% (10.1-12.4%) per annum for agents primarily affecting blood constituents and the smallest increase of 3.2% (2.3-4.0%) per annum for agents primarily affecting the cardiovascular system. Change of ADR-related hospitalisation due to vaccines was not statistically significant.
Medication therapeutic groups
Primary diagnostic group
Over 13 years, agranulocytosis was the predominant condition that warranted hospitalisation for ADR, accounting for 2.7% of all primary adverse effects, followed by nausea and vomiting (2.4%) and heart failure Figure 3 demonstrated a recent change, with renal impairments emerging as the leading adverse conditions. Admission for infections demonstrated the greatest increase over time (APC: 11.1%, 95% CI: 9.1-13.2%), followed by admission for musculoskeletal disorders (8.6%, 7.3-9.9%), mental and behavioural disorders (8.3%, 5.8-10.8%) and injury and poisoning (7.7%, 6.6-8.8%) ( Table 3) .
Discussion
This study demonstrated a significant increase of 5.8% per annum of ADR-related hospitalisations in NSW, with the age-adjusted incidence rate of ADR-related hospitalisations nearly doubled over 13 years. The observed increasing pattern was consistent with previous findings in Western Australia, England, the United States and Spain. 8, 9, 11, 12 Alarmingly, study cases with severe comorbid conditions and in-hospital deaths also increased over time, in comparison with a fairly steady trend of allcause in-hospital deaths in Australia (crude rates from 346.7 per 100 000 in 2005-2006 to 328.4 in 2014-2015), 21 reflecting an urgent need for clinical attention. A previous study has reported that more than half of ADR-related hospitalisations could be prevented. 22 Our findings emphasise the importance of continuing efforts to improve medication safety.
Elevated risk of ADR-related hospitalisations has been widely reported in older people as the ageing population is associated with the increased use of medication for chronic diseases.
1 Carrasco-Garrido et al. 8 found that, between 2001 and 2006, in Spain, patients older than 75 years were more likely to experience ADR, and the incidence rates of ADR in the aged population were much higher than those in adults aged 17-55 years and children. Patel et al. 10 found that, in England, patients over 60 years old accounted for 65% of the ADRrelated admissions. Adding to the existing literature, we found a similar pattern in older adults, with an increasing trend over time, who might experience ageingrelated physiological changes affecting medication pharmacokinetics and pharmacodynamics, use more medications or use medications incorrectly than their younger counterparts, therefore resulting in safety challenge of ADR. 23 A recent Australian study reported that approximately 89% of ADR-related hospitalisations in patients aged 65 years and over could be potentially prevented. 24 These findings highlight the need to include the use of existing medication pharmacogenomic, chemoinformatic and real-world clinical data to develop practical ADR risk mitigation tools for treating physicians, such as the Prediction of Hospitalisation due to Adverse Drug Reactions in Elderly CommunityDwelling Patients score. 25 ADR prevention strategies, such as medication reviews and patient education, may also have the utility to improve medication safety in this high-risk population group, such as the introduction of Pain MedsCheck trial programme aiming to reduce the burden of analgesic-related harm 26 and the Home Medicines Review (HMR) involving patients, their general practitioner and pharmacist to optimise medication use among patients with polypharmacy. 27 Although such a collaborative service in Australia has demonstrated benefits, with lower rates of ADR occurrence in patients receiving HMR versus their nonreceiving counterparts, 28 evidence regarding their effectiveness in ADR prevention in the hospital and primary care settings is limited. The regular involvement of 
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Internal Medicine Journal 49 (2019) 84-93 © 2018 Royal Australasian College of Physicians patients and health professionals, including clinical pharmacologists, pharmacists and nurses, in clinical decision-making may face real-world challenges, such as time constraints, tedious paperwork and lack of awareness in patients. Further efforts to improve multilateral communication and develop a standard electronic reporting system that is easy to use are warranted to enhance such collaborative services.
The leading therapeutic groups identified as causes of ADR hospitalisation were drugs to treat cardiovascular diseases, which have been the long-standing primary causes of deaths and disabilities in Australians, with associated healthcare burden continuing to grow. 29 Similarly, high incidence and an increasing trend of ADR hospitalisations caused by the analgesics might be related to the evident burden of musculoskeletal pain. 30 While therapeutic regimens remain conventional for these burdensome conditions, the associated adverse events have gradually attracted global attention for increasing morbidity, mortality and cost of care. 31 Over the current study period, opioids along with other pain medications, such as non-steroidal anti-inflammatory drugs, demonstrated an emerging trend as the leading causes of hospitalised adverse drug events. This upward trend coincides with the fourfold increase in pharmaceutical opioid use between 1990 and 2014 in Australia, 32 as well as a two-to threefold increase in North America and western and central Europe. 33 Among different types of pharmaceutical opioids, strong opioids, such as oxycodone, were commonly prescribed, 34 which may explain some of the ADR. Our study adds to the growing body of knowledge and reinforces the message calling for urgent attention and development of countermeasures. Without appropriate countermeasures, the ADR-related healthcare burden is anticipated to continue to grow.
Gender differences in hospitalised ADR have been discussed in many studies but remains unclear. Zopf et al. 35 conducted a prospective multicentre study and showed that females experienced 60% excess risk of ADR compared to males. However, the lack of a statistically significant difference was reported in the survey conducted in France, Italy and Spain. 36 In 2015, Yu et al. 37 conducted a systematic review to investigate variation of ADR in different genders across different medications and indicated the existence of gender differences in biological reactions to medication. This study also found ADR variation by gender across different medication agents, which more or less reflects gender differences in use or reaction pattern. For example, the trend of observed ADR-related hospitalisation caused by bacterial vaccines in females decreased by 7.1% per annum to a substantively greater extent than that in males, remaining fairly constant over time (APC: −0.5%, −5.8 to 5.2%). Future consideration of countermeasures should consider gender difference in both reactions to medications and patterns of use.
To the best of our knowledge, this study presents the most recent update on trends of ADR-related hospitalisation using a large-scale retrospective cohort in Australia. However, because the NSW APDC data did not comprise information on the exact use pattern of medications, for example, concurrent use of multiple medications or dose and frequency of use, speculation for the attribution of causality was not attempted. Although the specifications of ICD-10-AM codes used in this study indicate the causal link between proper medication use and related hospitalisations, the clinical symptoms and signs for admissions may be secondary to drug effects. In addition, the lack of comprehensive concordant coding of place of occurrence restricts our ability to differentiate between pre-admission ADR (subsequently diagnosed and addressed in hospital) and in-hospital ADR. There were some other limitations in this study. For example, the existence of unspecified codes would potentially result in misclassification errors when looking into subcategories. As the case selection criteria are based on codes that warrant hospitalisation, the observed increasing pattern is unlikely to be substantially influenced by misclassifications. The APDC data did not comprise the information of the severity of ADR, and the lack of these data limited our ability to identify whether there might be potential transitions between trends for cases of different severity, for example, a decreasing trend in hospitalised severe cases and increasing trend in less severe cases. The uses of separation outcome and severity of comorbidities could represent a proxy, and the findings did not support the existence of such a shift in severity of hospitalised ADR. Instead of a decreasing trend, we observed an increasing trend for in-hospital deaths and ADR-related hospitalisations with severe comorbidities, shedding light on the need for complex and focused intervention strategies. However, the caveat is that patients are much sicker than 13 years ago, who perhaps now live longer due to better medical care (but also require more complex polypharmacy to treat their multiple comorbidities) and would be more prone to ADR-related admissions, and thus, it is difficult to determine if an ADR is due to medication side effects or potential exacerbations of any underlying diseases. These findings have to be interpreted with caution as other factors, such as disease severity and drug-drug interactions, can account for this trend. We might still have a deficit in the knowledge required to identify effective interventions with targeting to reduce adverse drug events. The increasing trends in hospitalised ADR in this study clearly highlight the challenge to the healthcare system to improve medication safety, particularly among those vulnerable populations.
Conclusion
Although our study demonstrates significant increases in ADR-related hospitalisation over the past 13 years, attribution of these events to ADR is complex, particularly in this setting, and recording can be difficult. The increasing trends of ADR due to use of anticoagulants and opioidrelated analgesics and among high-risk patient groups, such as older people, warrant the future development of countermeasures to reduce the societal burden.
